Mobile

A study to compare the safety and effectiveness of F/TAF vs F/TDF (Truvada) once daily for the prevention of HIV, in men and transgender women who have sex with men and are at risk of HIV infection

Update Il y a 4 ans
Reference: EUCTR2016-001399-31

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is: - To assess the rates of HIV-1 seroconversion in men (MSM) and transgender women (TGW) who have sex with men who are administered daily F/TAF or F/TDF with a minimum follow-up of 48 weeks and at least 50% of subjects have 96 weeks of follow-up

Inclusion criteria

  • Healthy volunteers (Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus 1 (HIV-1))

Links